Navigation Links
Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
Date:9/18/2008

respiratory infections (including pneumonia, bronchitis), viral infections (including influenza, herpes infections), candidiasis, bacterial infection (including urinary tract infections), upper respiratory infection, dizziness (including vertigo), headache, neurologic sensation disorders (including paraesthesias), cough, nasopharyngeal pain, diarrhea, abdominal pain, stomatitis and mouth ulceration, nausea, hepatic enzymes increased, rash, pruritus, musculoskeletal pain, pyrexia, fatigue (including asthenia and malaise). Adverse drug reactions reported post-marketing include intestinal perforation, interstitial lung disease including pulmonary fibrosis and cutaneous vasculitis.

About HUMIRA

HUMIRA is the only fully human monoclonal antibody approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), psoriasis, ankylosing spondylitis (AS), Crohn's disease and juvenile idiopathic arthritis (JIA) in the United States and Europe. HUMIRA resembles antibodies normally found in the body. It works by blocking tumor necrosis factor alpha (TNF-alpha), a protein that, when produced in excess, plays a central role in the inflammatory responses of many immune-mediated diseases. To date, HUMIRA has been approved in 76 countries and more than 270,000 people worldwide are currently being treated with HUMIRA. Clinical trials are also under way evaluating the potential of HUMIRA in ulcerative colitis.

In Europe, HUMIRA, in combination with methotrexate (MTX), is indicated for the treatment of moderate to severe, active RA in adult patients when the response to disease-modifying anti-rheumatic drugs (DMARDs) including MTX has been inadequate, and for the treatment of severe, active and progressive RA in adults not previously treated with MTX. HUMIRA can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. HUMIRA has been shown to reduce the rate of progression of joint damage as measu
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
2. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
3. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
4. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
5. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
6. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
7. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
8. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
9. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
10. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
11. Keraderm to Release $100 Phototherapy Treatment for Fungal Nail Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... N.C. , Aug. 22, 2014  Medical Science ... and thought leaders in the healthcare sector. As the ... the iPad is changing how Medical Science Liaisons (MSLs) ... MSLs are using the tablet to not only ... also to better coordinate thought leader interactions across geographies ...
(Date:8/22/2014)... , August 22, 2014 ... Markets ( http://www.researchandmarkets.com/research/x34qgv/global_laboratory ) has announced the addition ... 2014-2018"  report to their offering.  ... is an essential instrument for any modern ... precise weighing of materials. It can be ...
(Date:8/22/2014)... , August 22, 2014 ... has announced the addition of the  "Global ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... with a sterile environment in a healthcare ... is equipped with technically advanced equipment, which ...
Breaking Medicine Technology:iPads Enhancing Medical Science Liaison Interactions with Thought Leaders, New Study Shows 2Global Laboratory Electronic Balance Market 2014-2018: Key Vendors are A&D Company, Mettler-Toledo, Sartorius and Thermo Fisher 2Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2
... STXS ) announced today that it intends, subject ... in a registered public offering pursuant to its existing shelf ... intends to grant the underwriters of the offering an option ... if any. Stereotaxis plans to use the proceeds ...
... Diabetes experts at a meeting convened by the U.S. ... of Health (NIH) took the next step in advancing ... forth clinical recommendations to ensure the safe and effective ... are pleased at today,s meeting there was a strong ...
Cached Medicine Technology:Stereotaxis Announces Public Offering of Common Stock 2Stereotaxis Announces Public Offering of Common Stock 3Stereotaxis Announces Public Offering of Common Stock 4JDRF Clinical Panel Recommends Next Steps for Artificial Pancreas Clinical Testing 2JDRF Clinical Panel Recommends Next Steps for Artificial Pancreas Clinical Testing 3JDRF Clinical Panel Recommends Next Steps for Artificial Pancreas Clinical Testing 4
(Date:8/23/2014)... Dallas, Texas (PRWEB) August 23, 2014 ... deterioration of the function of the myocardium (the ... heart failure; common symptoms are dyspnea (breathlessness) and ... cardiomyopathy are often at risk of dangerous forms ... The most common form of cardiomyopathy is dilated ...
(Date:8/23/2014)... "I have heard female patients complain about making ... an inventor from Lake Stevens, Wash. "In order to ... up with this urine-collection aid." , He developed the ... from women more easily. The accessory prevents messes. It ... The invention improves sanitation and prevents the spread of ...
(Date:8/23/2014)... 2014 "Many men refuse to touch ... up getting covered in urine and spit," said an ... bathroom situations, I came up with this hygienic device." ... a man raises the toilet seat before urinating. The ... This reduces contact with dirt and germs. The accessory ...
(Date:8/23/2014)... 2014 The report “Polycarbonate Resin ... Forecasts to 2018” defines and segments the global ... the global revenue and consumption. It also identifies ... resin market with analysis of trends, opportunities, burning ... consumption and revenues are forecasted on the basis ...
(Date:8/23/2014)... 2014 GranuFlo lawsuit ( http://www.thegranuflolawsuit.com ... NaturaLyte dialysis concentrate recall continue to mount in ... Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... the U.S. Judicial Panel on Multidistrict Litigation (JPML) ... pending in the proceeding. In July, the Panel ...
Breaking Medicine News(10 mins):Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 2Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 3Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 4Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 3Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 4Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 4
... Taclonex; Company ... ST. DAVID,S, Bermuda, Nov. 9 Warner Chilcott,Limited (Nasdaq: ... 2007. Revenue in the quarter ended September 30, 2007 totaled,$226.5 million, ... of the increase in revenue were the net sales of two,products ...
... and Send ... Delegation, OAKLAND, Calif., ... have,donated $10,000 in support of RNs striking in Kentucky and West Virginia,and ... as part,of a solidarity caravan to join the action against Appalachian Regional,Healthcare ...
... BASKING RIDGE, N.J., Nov. 9 Hooper Holmes,Inc. (Amex: ... services,today announced financial results for the third quarter ended ... million compared to $60.6,million in the corresponding period of ... quarter of 2007 of $10.6 million, or $(0.16) per ...
... due to non-recurring event in 2007, net loss stable ... Canadian dollars unless otherwise noted), BELLEVILLE, ON, Nov. ... research-based, technology-driven Canadian,biopharmaceutical company, today announced financial results for ... 30, 2007. "We are also focused on the ...
... Warrant Redemption To Reduce Debt and Enhance Financial Flexibility To Fund ... ... 9 Smart Balance, Inc.,(Nasdaq: SMBL ) today announced its results ... third quarter of 2007, the Company,reported net sales of approximately $42 million ...
... Pa. and SAN DIEGO, Nov. 9 ,RS&A, Inc. ... oncology equipment sales and service, announced today that ... Oncology Systems, Inc.,(ROS), an oncology and diagnostic imaging ... US provider of oncology equipment service,and distributor of ...
Cached Medicine News:Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 18Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 19Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 20Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 21Health News:Nurses From Across Nation Join Solidarity Caravan in Support of Striking Kentucky RNs 2Health News:Hooper Holmes Announces Third Quarter 2007 Results 2Health News:Hooper Holmes Announces Third Quarter 2007 Results 3Health News:Hooper Holmes Announces Third Quarter 2007 Results 4Health News:Hooper Holmes Announces Third Quarter 2007 Results 5Health News:Hooper Holmes Announces Third Quarter 2007 Results 6Health News:Hooper Holmes Announces Third Quarter 2007 Results 7Health News:Bioniche Reports Fiscal 2008 First Quarter 2Health News:Bioniche Reports Fiscal 2008 First Quarter 3Health News:Bioniche Reports Fiscal 2008 First Quarter 4Health News:Bioniche Reports Fiscal 2008 First Quarter 5Health News:Bioniche Reports Fiscal 2008 First Quarter 6Health News:Bioniche Reports Fiscal 2008 First Quarter 7Health News:Bioniche Reports Fiscal 2008 First Quarter 8Health News:Bioniche Reports Fiscal 2008 First Quarter 9
The Concept Plus also allows users to transfer large bottles, flasks and other equipment, quickly and efficiently. The front-loading interlock features class leading one touch operation and easy acce...
Providing a perfect combination of capacity, speed and innovation, the Concept 400 delivers simple sophistication and new levels of comfort and convenience....
Lose the variability of anaerobic jars and step into the 21st century with the anaerobic workstation that provides the answer to the common problems associated with anaerobic microbiology....
... Enduro is the ideal partner when ... before, during or directly after an ... adjustment and the filigreed construction, MARS ... examination, induction and operating theatre. Universal ...
Medicine Products: